Sanofi: FDA Approves Use of 0.5 mL Dose of Influenza Vaccine in Children as Young as 6 Months of Age

Originally Published by Sanofi.

The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) to include children age 6 through 35 months. Sanofi Pasteur, the vaccine division of Sanofi, will have the 0.5 mL dose, in addition to the 0.25 mL dose, available for the upcoming 2019-20 season for this expanded age range.


“Offering pediatricians the convenience of the same 0.5 mL dose option for children, may help streamline immunization efforts,” said Dr. David P. Greenberg, Regional Medical Head North America, Sanofi Pasteur. “The potentially life-threatening effects of influenza in children reported during the 2017-18 season, especially among those who were not vaccinated, is sobering. We commit ourselves every day to bring solutions to help meet ongoing public health needs related to influenza, especially among vulnerable groups such as young children.”

Today’s approval is supported by clinical data from a Phase IV safety and immunogenicity study conducted in nearly 2,000 children, which demonstrated that one or two doses of 0.5 mL of vaccine in children 6 through 35 months of age had a safety profile that was comparable to one or two doses of 0.25 mL of vaccine with no new safety concerns observed, and induced a robust immune response. Detailed results were presented at the Pediatric Academic Societies meeting in April 2018, as well as at the Advisory Committee on Immunization Practices meeting and the American Academy of Family Physicians Family Medicine Experience conference in October 2018.

Sanofi Pasteur’s flu vaccine portfolio includes options to help protect all eligible patients from influenza. In addition to Fluzone Quadrivalent vaccine, the product portfolio includes Flublok Quadrivalent (influenza vaccine) and Fluzone High-Dose (influenza vaccine), the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators in randomized controlled trials. In these same trials, the most common local and systemic adverse reactions to Flublok Quadrivalent and Fluzone High-Dose vaccines include pain at the injection site, headache and myalgia.

Health care providers can place 2019-20 reservations for all Sanofi Pasteur vaccines, including the 0.5 mL presentations of Fluzone Quadrivalent vaccine for use in all appropriate pediatric patients via www.VaccineShoppe.com. The 0.25 mL dose of Fluzone Quadrivalent vaccine will remain available for 2019-20 reservations.

Latest News

black female exec

5 Ways to Enhance Your Executive Presence

Advancing your career and finding the right employer and position fit doesn’t have to be complicated. There are things you can do each day to advance toward your dream job and thrive at work. The following article is part of a 5 Ways Series that offers resources and tips on…

AbbVie: Scientists Rock! Row, Row, Row Your Boat

Originally published on AbbVie.com Scientists Rock! is a monthly Q&A where we pull an AbbVie scientist out of the lab to hear what makes them tick. This month we travel to Cambridge, Massachusetts, United States, to chat with Samantha Brecht, associate scientist, AbbVie Foundational Neuroscience Center. Once upon time, in…

Michael brown

Police Officer Who Killed Michael Brown Won’t Face Charges

Darren Wilson, the former officer in Ferguson, Missouri, who, in 2014 fatally shot Michael Brown, an unarmed Black teenager, will not face any charges, the Washington Post reports. St. Louis County’s top prosecutor, Wesley Bell, said at a news conference on Thursday that his office investigated the case, including witness statements, forensic…